The Effect of GIP(3-30)NH2

Endocrine - Other Clinical Trial

— GA-10  

Official title:

The Effect of GIP(3-30)NH2

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03770910
• Other study ID #: SDCC_CMP_GA-10
• Status: Completed
• Phase: N/A
• Start date: December 6, 2018
• Est. completion date: December 1, 2019

Study information

• Verified date: March 2020
• Source: University Hospital, Gentofte, Copenhagen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Infusion of glucose-dependent insulintropic polypeptide (GIP) receptor antagonist and evaluation of effect of insulin secretion in healthy subjects.

Description:

Infusion of glucose-dependent insulintropic polypeptide (GIP) receptor antagonist and evaluation of effect of insulin secretion in healthy subjects.

Six study hyperglycemic clamps (10 mmol/l) pr. participant.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 8
• Est. completion date: December 1, 2019
• Est. primary completion date: March 1, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Healthy

• BMI 19-28 kg/m*m

• Stable body weight

Exclusion Criteria:

• Diabetes

• Anemia

• First-degree relatives with diabetes

Related Conditions & MeSH terms

• Endocrine - Other

Intervention

Other:
• GIP receptor antagonist
GIP receptor antagonist
• GIP receptor agonist
GIP(1-42)
• Saline
Placebo (vehicle for infusions)

Locations

Country	Name	City	State
Denmark	Clinical Metabolic Physiology	Copenhagen	Gentofte
Denmark	Clinical Metabolic Physiology	Gentofte	Copenhagen

Sponsors (3)

Lead Sponsor	Collaborator
University Hospital, Gentofte, Copenhagen	Steno Diabetes Center Copenhagen, University of Copenhagen

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Insulin secretion	Insulin secretion rates (ISR) calculated from serum levels of C-peptide	8 weeks